Work

Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Year: 2016

Type: article

Abstract: Myeloid sarcoma (MS) is a rare neoplasm consisting of immature myeloid cells that forms a tumor mass at an anatomic site other than the bone marrow (BM). 1 MS may develop de novo or secondary to other types of myeloid neoplasm. MS is most often associated with acute myeloid leukemia (AML), and develops in 2–5% of AML patients. 2 , 3 Less frequently, MS can arise in patients with chronic myelogenous leukemia (CML), mainly in the setting of blast phase (BP) or accelerated phase (AP). 3 , 4 , 5 Traditionally, MS is considered the equivalent of AML, and is one of diagnostic criteria for CML-BP, regardless of the blast count in the BM or peripheral blood. According to the 2008 World Health Organization criteria, CML-BP can be diagnosed when: (1) blasts are ⩾ 20% in the BM or peripheral blood (medullary BP); or (2) there is an extramedullary blast proliferation, in other words, MS.

Source: Blood Cancer Journal

DOI: 10.1038/bcj.2016.27